Hereditary Angioedema Treatment Market was Worth US$ 1883.1Mn in 2017, Increasing Healthcare Expenditure to Enable Growth | Fortune Business Insights

The report classifies the Global Hereditary Angioedema Treatment Market in various segments and offer a comprehensive overview. The Global Hereditary Angioedema Treatment Market to gain from increasing incidences of genetic mutation.

Pune, India - May 16, 2019 /MarketersMedia/ —

The Global Hereditary Angioedema Treatment Market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview. The Global Hereditary Angioedema Treatment Market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017.

According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to the high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute to the expansion of the hereditary angioedema treatment market in North America.

Request Sample Copy at https://www.fortunebusinessinsights.com/enquiry/sample/hereditary-angioedema-treatment-market-100164

The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, an increasing number of product innovations in the region backed by the high presence of hereditary angioedema drugs manufacturers will give tailwinds to the growth witnessed by the hereditary angioedema treatment market.

C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period

In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.

Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment are expected to boost the global market.

According to the U.S. Hereditary Angioedema Association, hereditary angioedema may not necessarily occur due to the prior familial history of the disease. In 25% of the cases, hereditary angioedema may arise due to spontaneous mutation of the gene called C-1 inhibitor. This is anticipated to enable growth in the global hereditary angioedema treatment market.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164

On the flip side, the side effects and high cost associated with hereditary angioedema drugs and treatment is the major factor that may restrain the global hereditary angioedema treatment market.

Shire, CSL Behring, and Pharming Group NV to Lead the Global Market

The Global Hereditary Angioedema Treatment Market is witnessing the entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India
Phone: +1 424 253 0390
Website: https://www.fortunebusinessinsights.com

Source URL: https://marketersmedia.com/hereditary-angioedema-treatment-market-was-worth-us-18831mn-in-2017-increasing-healthcare-expenditure-to-enable-growth-fortune-business-insights/513433

Source: MarketersMedia

Release ID: 513433

Latest News

NTSB: Autopilot was in use before Tesla hit semitrailer

May 24, 2019

DETROIT — A Tesla Model S involved in a fatal crash with a semitrailer in Florida March 1 was operating on the company's semi-autonomous Autopilot system, federal investigators have determined. The car drove beneath the trailer, killing the driver, in a crash that is strikingly similar to one that happened on the other side of Florida in 2016 that also involved use of Autopilot. In both cases, neither the driver nor the Autopilot system stopped for the trailers, and the roofs of the cars were sheared off. The crash, which remains under investigation by the National Transportation Safety Board and...

Schools turn to technology to reduce toll during shootings

May 24, 2019

LOS ANGELES — Efforts to combat school shootings are shifting toward software and other technology to reduce the number of victims. Security experts say gunshot detection systems, apps and artificial intelligence are becoming more common because school attacks, while relatively rare, have been among the deadliest mass shootings in U.S. history. The technology is often used in combination with mental health and anti-bullying programs. Schools in Beverly Hills and others nationwide are adopting a strategy that aims to speed up the law enforcement response to shootings. Beverly Hills officials have added armed security guards, surveillance cameras and an app to...

Self-driving vehicle pulled over by curious police officer

May 24, 2019

PROVIDENCE, R.I. — A self-driving shuttle got pulled over by police on its first day carrying passengers on a new Rhode Island route. Providence Police Chief Hugh Clements said an officer pulled over the odd-looking autonomous vehicle because he had never seen one before. "It looked like an oversize golf cart," Clements said. The vehicle, operated by Michigan-based May Mobility, was dropping off passengers Wednesday morning at Providence's Olneyville Square when a police cruiser arrived with blinking lights and a siren. It was just hours after the public launch of a state-funded pilot for a shuttle service called "Little Roady."...

New security flaw in Intel chips could affect millions

May 24, 2019

SANTA CLARA, Calif. — Intel has revealed another hardware security flaw that could affects millions of machines around the world. The chipmaker said Tuesday there's no evidence of anyone exploiting the bug outside of a research laboratory. "Doing so successfully in the real world is a complex undertaking," Bryan Jorgensen, Intel's senior director of product assurance and security, said in a video statement. The bug is embedded in the architecture of computer hardware. But "with a large enough data sample, time or control of the target system's behavior," Jorgensen said, the flaw could enable attackers to see leaked data. It's...

Uber to give its market value a lift in stock market debut

May 24, 2019

SAN FRANCISCO — Uber's next stop is the stock market, where it hopes to pick up more investors willing to bet on a ride-hailing market brimming with potential and conspicuously lacking in profits. The world's largest ride-hailing service reached a major milestone Thursday when Uber priced its long-awaited initial public offering at $45 price per share to set the stage for its stock to begin trading Friday morning. The IPO came in at the lower end of Uber's targeted price range of $44 to $50 per share. The caution may have been driven by escalating doubts about the ability of...

Sign up now!